Skip to main content
Premium Trial:

Request an Annual Quote

Eric Fung, Simon Shorter, Bjrn Ekstrm, John Murphy, Robert Friel, John Roush, Douglas Obenshain, Mor Amitai

Premium

Eric Fung has been promoted within Ciphergen’s diagnostic division to vice president of clinical and medical affairs. In his new position, Fung will manage biomarker discovery efforts within academic collaborations and direct clinical trial studies designed to achieve commercialization, the company said.

Ciphergen has also appointed Simon Shorter as vice president of business development. In his position, Shorter will oversee corporate strategy and academic business development activities, the company said.


Björn Ekström has become CEO of Olink Bioscience, a Swedish company founded in September that focuses on protein analysis technology. Previously, he was EVP and head of R&D at Pyrosequencing. He also held several positions within R&D at Amersham Biosciences and Pharmacia Biotech.


Perkin Elmer announced this week that it has named John Murphy executive vice president and chief operating officer. In this newly-created position, Murphy will oversee activities in improving operational efficiencies with particular emphasis on the supply chain. In addition, he will oversee the company’s strategy to expand medical imaging applications across health sciences markets and lead the company’s China growth strategy.

In addition, Perkin Elmer appointed Robert Friel as executive vice president and chief financial officer for business development, and John Roush as president of the company’s optoelectronics business. Friel had served as chief financial officer since 1999, and will now also direct the company’s business development activities, focusing on strategic growth opportunities in health sciences and select advanced technologies. Roush had previously served as general manager of two business units within the Optoelectronics division.


The Burnham Institute last week announced that Douglas Obenshain has been elected to its board of trustees. Obenshain is a partner with Ernst & Young, where his practice focuses primarily on biotechnology, pharmaceutical, and medical device companies, the institute said.


Mor Amitai will step down as president and CEO of Compugen by the end of 2005, the Tel Aviv-based company said last week. Compugen is now searching for a new CEO with more experience in pharmaceutical product development and commercialization.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.